Cover Image
Market Research Report
Product code 
1074122

Global Neglected Tropical Diseases Diagnosis Market - 2022-2029

Published: | DataM Intelligence | 200 Pages | Delivery time: 2 business days

Price

Back to Top
Global Neglected Tropical Diseases Diagnosis Market - 2022-2029
Published: May 7, 2022
DataM Intelligence
Content info: 200 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global neglected tropical diseases diagnosis market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Neglected tropical diseases (NTDs) are a series of 20 diseases mostly found in tropical areas, where they disproportionately impact poor people, women and children. People suffer from terrible health, societal, and economic effects due to these disorders. POC diagnostic is an approach to identify and possibly quantify a specific analyte. Based on the variety of biomolecular ways to detect specific analytes, POC tests can be classified into immunological tests, nucleic acid-based tests, and other biomarker-based tests.

Market Dynamics

Innovative technologies to diagnose Neglected Tropical Diseases are expected to drive market growth.

LAMP (loop-mediated isothermal amplification) due to its sensitivity, specificity, speed, low cost, and tolerance to inhibitors has become the preferred approach, accounting for 60% of all INAAT publications. The use of LAMP technology in diagnosing bacterial, viral, fungal, and parasite illnesses in humans, animals, and plants is well-established. Compared to PCR-based approaches, the simplicity of LAMP makes it excellent for field testing in underdeveloped nations and for developing point-of-care molecular diagnostic tools. A wide range of approaches to integrating LAMP technology into a field-friendly display have been published, including lateral flow dipstick and lab-on-chip layouts, microfluidic-based methods, in combination with metallic nanoparticles, and combination with smartphone-based technology.

Additionally, the World Health Organization (WHO) is looking into how mobile phone technology might help them handle various global public health challenges. In response, the Department of Neglected Tropical Diseases recently transformed a 2018 graphic teaching guide on neglected tropical diseases of the skin (also known as skin NTDs) into an interactive new mobile phone application. This software application will immediately offer information about a certain disease, including clinical symptoms, management, geographic distribution, and a list of possible diagnoses, to health care workers and the general public. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The high costs of diagnostic tests and kits, their research and development activities, and a shortage of skilled professionals for accurate diagnosis are a few factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. During the pandemic urgent need to develop diagnostics for COVID-19 has resulted in the already under-resourced development and manufacturing of rapid diagnostic tests (RDTs) and molecular tests for many tropical diseases being placed on hold. Contact tracing for all patients with laboratory-confirmed COVID-19 has been one of the strategies adopted by ministries of health to interrupt transmission and curb the incidence. Such an approach is highly successful for other diseases. For instance, early case detection (through contact tracing) and prompt treatment have been the cornerstones in the fight against leprosy. Visceral leishmaniasis elimination programs in the Indian subcontinent have also relied on identifying people with fever through 'fever camps.' Thus, integrating COVID-19 testing into local health services, or piggybacking onto certain NTD programs with well-organized testing capabilities, provides a unique opportunity for increasing COVID-19 testing, especially in harder-to-reach populations.

Additionally, Cases are being tracked, and those at risk of SARS-CoV-2 infection are identified using smartphone applications and other phone-based technology. Due to the fragility of the internet network and the common use of smartphones in NTD endemic areas, these technologies may not be practical to implement. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Point-of-care Testing segment is expected to hold the largest market share in neglected tropical diseases diagnosis market

The point-of-care testing segment is expected to dominate in 2020. The segment's growth benefits due to their cost-effectiveness and user-friendliness. Point-of-care (POC) testing services are increasingly employed as diagnostic tools for rapidly detecting neglected tropical diseases in POC settings. The capacity of point-of-care (POC) testing services to give timely actionable information for patient care during a visit to the healthcare system fuels the growth of the neglected tropical diseases diagnosis market. For instance, The Chagas Detect Plus Rapid Test Kit recently received 510K clearance from the US FDA. InBios International created this POCT to treat Chagas disease. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global neglected tropical diseases diagnosis market

In 2020, North America accounted for the highest revenue share. The growing demand for rapid diagnostic tests for the treatment of lymphatic filariasis, increasing awareness among the people, well-established infrastructure, rise in the adoption of point-of-care testing services in the region are some of the factors the market is expected to boost in the forecast period. For instance, PATH and Standard Diagnostics (SD), a global leader in fast diagnostics (bought by Abbott in 2017), collaborated to create three serology-based lateral flow assays that check for exposure to oncho and LF by identifying antibodies. All three tests require only a single drop of blood from a finger prick, making them simpler to perform and more widely accepted. The tests are intended for use in rural areas where tough conditions exist, and they offer results in less than 30 minutes. These tests do not need to be synchronized with mass medication administration because they detect antibodies and can be done at any time of day. SD BIOLINE Lymphatic Filariasis IgG4 test is designed for use in regions where LF is endemic, and this test detects antibodies to Wb123 for LF alone. The Wb123 does not cross-react with Loa loa infections. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the neglected tropical diseases diagnosis market are Abbott Laboratories, Bio-Rad Laboratories, Inc., Coris BioConcept, Genome Diagnostics Pvt. Ltd, InBios International, Inc., Oscar Medicare Pvt Ltd., Thermo Fisher Scientific, Inc., ZeptoMetrix, LLC, Premier Medical Corporation Ltd. and EUROIMMUN Medizinische Labordiagnostika AG

Abbott Laboratories:

Overview:

Abbott Laboratories (Abbott) develops manufactures, and markets diagnostic devices, diabetes care, vision technologies, vascular products, and nutrition and animal health products. The company provides innovative medical devices to fulfill unmet healthcare needs. The company provides drug testing products and solutions through its diagnostics segment. Abbott Vascular, a global leader in the Cervical Cancer Diagnostics medical device industry, provides innovative, minimally invasive and cost-effective products to treat coronary artery disease. The company offers an extensive portfolio of drug-eluting stents, bare-metal stents, coronary guide wires, balloon dilatation catheters, and guiding catheters and accessories. Abbott Laboratories operates its business in over 150 countries worldwide.

Panbio DENGUE DUO CASSETTE: The Panbio Dengue Duo Cassette is for the qualitative presumptive detection of IgM and elevated high titre IgG antibodies to dengue virus in human serum, plasma and whole blood.

Why Purchase the Report?

Visualize the composition of the neglected tropical diseases diagnosis market segmentation by disease, diagnostic method, service type, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in neglected tropical diseases diagnosis market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of neglected tropical diseases diagnosis market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global neglected tropical diseases diagnosis market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Product Code: DMCD4906

Table of Contents

1. Global Neglected Tropical Diseases Diagnosis Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Neglected Tropical Diseases Diagnosis Market - Market Definition and Overview

3. Global Neglected Tropical Diseases Diagnosis Market - Executive Summary

  • 3.1. Market Snippet by Disease
  • 3.2. Market Snippet by Diagnostic Method
  • 3.3. Market Snippet by Service Type
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Neglected Tropical Diseases Diagnosis Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovative technologies to diagnose Neglected Tropical Diseases are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high costs of diagnostic tests and kits are expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Neglected Tropical Diseases Diagnosis Market - Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. Global Neglected Tropical Diseases Diagnosis Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Neglected Tropical Diseases Diagnosis Market - By Disease

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 7.1.2. Market Attractiveness Index, By Disease Segment
  • 7.2. Dengue*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Chikungunya
  • 7.4. Rabies
  • 7.5. Lymphatic Filariasis
  • 7.6. Buruli Ulcer
  • 7.7. Leprosy
  • 7.8. Others

8. Global Neglected Tropical Diseases Diagnosis Market - By Diagnostic Method

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 8.1.2. Market Attractiveness Index, By Diagnostic Method Segment
  • 8.2. Conventional Method*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Molecular Method

9. Global Neglected Tropical Diseases Diagnosis Market - By Service Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Type
    • 9.1.2. Market Attractiveness Index, By Service Type Segment
  • 9.2. Centralized Service*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Point-of-care Testing

10. Global Neglected Tropical Diseases Diagnosis Market - By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinical Laboratories
  • 10.4. Others

11. Global Neglected Tropical Diseases Diagnosis Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Method
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Neglected Tropical Diseases Diagnosis Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Global Neglected Tropical Diseases Diagnosis Market- Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Bio-Rad Laboratories, Inc.
  • 13.3. Coris BioConcept
  • 13.4. Genome Diagnostics Pvt. Ltd
  • 13.5. InBios International, Inc.
  • 13.6. Oscar Medicare Pvt Ltd.
  • 13.7. Thermo Fisher Scientific, Inc.
  • 13.8. ZeptoMetrix, LLC
  • 13.9. Premier Medical Corporation Ltd.
  • 13.10. EUROIMMUN Medizinische Labordiagnostika AG

LIST NOT EXHAUSTIVE

14. Global Neglected Tropical Diseases Diagnosis Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us